PerkinElmer Participates in Multinational Clinical Trial Focused on Low-Dose Aspirin Therapy for Prevention of Early Onset Preeclampsia

PerkinElmer Participates in Multinational Clinical Trial Focused on Low-Dose Aspirin Therapy for Prevention of Early Onset Preeclampsia

July 14, 2014 at 12:00 AM EDT
WHAT: PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment and an innovator in the field of prenatal screening for more than thirty years , today announced its participation in a three-year multinational study focused on the prediction and prevention of preeclampsia.

The Fetal Medicine Foundation’s Project “ASPRE” study, sponsored by the Seventh Framework Programme of the European Union and administered by University College London, will examine the impact of low-dose aspirin therapy for potential prevention of early onset preeclampsia. PerkinElmer’s PlGF 1-2-3™ screening kit, combining first trimester blood test results with ultrasound and blood pressure measurements, was selected as the test to be used in this study.

Preeclampsia, which affects approximately five to seven percent of all pregnancies, is a sudden increase in blood pressure and protein in the urine, which can occur after the 20th week of pregnancy and often leads to the delivery of the fetus prior to full term. It can lead to convulsions, a condition known as eclampsia, which may result in serious health complications for a mother and her baby.

Early onset preeclampsia, affecting 0.7 percent of pregnancies, often contributes more to the pregnant mother’s and baby’s risks of morbidity and mortality. If found early, options such as increased monitoring, modified activity, bed rest and medication can help reduce or avoid complications related to early onset preeclampsia.

“Although there is no known cure for preeclampsia, we are committed to advancing research, including participating in this extensive three-year study, that can help women take careful measures during pregnancy to prevent or minimize their symptoms and reduce the overall prevalence of this condition,” said Dr. Kypros Nicolaides, Director of Harris Birthright Research Centre for Fetal Medicine at King's College London and Chairman of the Fetal Medicine Foundation. “One of the important methods of treatment we are examining is the use of medications in high risk expectant mothers, including administering low doses of aspirin. Leveraging PerkinElmer’s prenatal screening capabilities will help us to observe the possible impacts of this therapy early on, during the first trimester.”

“As a global leader in prenatal screening, PerkinElmer is pleased to be an integral part of this innovative study by providing our testing capabilities and expertise to help make a difference in the lives of expectant mothers and their babies,” said Prahlad Singh, President, Diagnostics, PerkinElmer. “As the first company to develop a preeclampsia screening test for the first trimester in 2010, we have been collaborating with key researchers for several years to study this condition -- and we hope these efforts will lead to better outcomes.”
MORE: Globally, preeclampsia and other hypertensive disorders of pregnancy are a leading cause of maternal and infant illness and death. By conservative estimates, these disorders are responsible for 76,000 maternal and 500,000 infant deaths each year, according to the Preeclampsia Foundation.

PerkinElmer also offers the PreeclampsiaScreen™ | T1 serum screening test, the first available early onset preeclampsia testing service, to physicians in the United States. This laboratory-developed test enables physicians to more precisely detect asymptomatic patients in the first trimester of pregnancy who are at high risk for developing the dangerous condition, allowing for earlier identification, management and intervention. It can be administered at the same time as other first trimester screening tests (including screening for Down syndrome) and requires a simple blood draw.

If you are a healthcare provider in the U.S., contact PerkinElmer to begin ordering the screening test for your practice. If you are a pregnant mother, please ask your healthcare provider for more information about preeclampsia and this screening test.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2.2 billion in 2013, has about 7,600 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Media Contact:
Jesse Steinberg
jsteinberg@apcoworldwide.com
+1-646-556-9324

Related Links

IR Contact

ir@perkinelmer.com
(781) 663 - 6900
940 Winter Street
Waltham, MA 02451
United States
www.perkinelmer.com

Transfer Agent

Mailing addresses
Correspondence should be mailed to:
Computershare
P.O. Box 505000
Louisville, KY 40233

Overnight correspondence should be sent to:
Computershare
462 South 4th Street, Suite 1600
Louisville, KY 40202

Shareholder website www.computershare.com/investor
Shareholder online inquiries
www-us.computershare.com/investor/Contact